Latest News
Cure SMA Launches Their “This Gen Next 10” Campaign
Today, Cure SMA is proud to launch our year-end campaign: This Gen, Next 10. It’s a chance to look at where this community started, how far we’ve come, and what […]
Adults with SMA Share Their Unmet Needs and Independence Barriers in Washington D.C.
This week, the unmet health and everyday living needs of adults with spinal muscular atrophy (SMA) took center stage in Washington, DC, in an event organized by Cure SMA. Adults […]
Biogen Shares Update on the Salanersen Development Program
(opens in new tab) From newly opened Phase 3 studies enrolling infants through adults to the first participants already dosed in the U.S. and Japan, Biogen shares an update on […]
The 2026 Annual SMA Research & Clinical Care Meeting Summaries Are Here!
In June, SMA researchers and clinicians from around the world gathered in Orlando for the 30th Annual SMA Research & Clinical Care Meeting – to share early findings, compare notes […]
Scholar Rock Receives Approval for ISEMBYLD™ for the Treatment of SMA
Scholar Rock today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ISEMBYLD™ (apitegromab-mstn) to treat spinal muscular atrophy (SMA) in adults and children […]
Genentech Shares Highlights from an Unforgettable Week at the Annual SMA Conference
(opens in new tab) From a lively “Evryday Café” exhibit hall experience to an advocacy reception featuring conversations on policy and access, Genentech recaps a full week connecting with the […]